Skip to main content
Premium Trial:

Request an Annual Quote

Schott Licenses Microarray Slide Surface Chemistry from Accelr8

NEW YORK, Dec. 6 (GenomeWeb News) - Schott Nexterion has taken an exclusive license to surface chemistry for microarrays from Accelr8 Technology, Accelr8 said today.

 

The deal follows an earlier agreement under which Schott sold Accelr8 microarray slides under its name. Schott, based in Jena, Germany, now obtained a two-year exclusive manufacturing and marketing license to Accelr8's OptiChem-coated microarrays for protein applications, which can be extended for one year.

 

The company also took a non-exclusive license for other microarray applications. Accelr8 will be Schott's only supplier of permeable hydrogel coatings for microarray slides during that time.

 

Accelr8 will continue to manufacture OptiChem slides for Schott until Schott's own production facility goes online next April.

 

In addition, Schott has obtained an option for a technology transfer license for multiplexed microarray plates in multi-well microtiter plate format from Accelr8.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.